Management of Uncontrolled Hypertension on Dual Therapy

Assessment of Current Blood Pressure Control

The recorded office blood pressure of 138–148 mmHg systolic / 90–96 mmHg diastolic meets Stage 1 hypertension according to the 2025 ACC/AHA guideline (target < 130/80 mmHg) and is considered uncontrolled by the 2024 ESC guideline (minimum target < 140/90 mmHg)【4】【5】.
Failure to reach target on an ARB + CCB regimen indicates the need to escalate to a three‑drug combination【1】【2】【3】.

All major hypertension societies (ISH 2020, ESC 2024, ACC/AHA 2025) recommend adding a thiazide or thiazide‑like diuretic as the third agent when dual therapy is insufficient【1】【3】【4】【5】.

Chlorthalidone 12.5–25 mg once daily is preferred over hydrochlorothiazide because of its longer duration of action and superior cardiovascular outcome data【1】【4】.
Indapamide 1.25–2.5 mg once daily is an equally effective thiazide‑like alternative【1】【5】.
Hydrochlorothiazide 25 mg may be used when thiazide‑like agents are unavailable, though it is less preferred【4】.

The ARB blocks the renin‑angiotensin system, the CCB provides vasodilation, and the thiazide‑like diuretic reduces extracellular volume, producing synergistic blood‑pressure lowering【1】【4】【5】.
This three‑drug regimen is endorsed as the standard initial triple therapy by ISH 2020, ESC 2024, and ACC/AHA 2025 guidelines【1】【3】【4】【5】.

Switching to an SPC containing an ARB, a CCB, and a thiazide improves medication adherence and reduces cardiovascular events, as shown in the 2025 Circulation and 2024 European Heart Journal studies【4】【5】.

Medication non‑adherence is the most common cause of apparent treatment failure; clinicians should directly inquire about missed doses and barriers【2】.
Home blood‑pressure monitoring (target < 135/85 mmHg) or 24‑hour ambulatory monitoring (target < 130/80 mmHg) should be performed to exclude white‑coat effect【1】【3】【5】.
Office measurements can overestimate true blood pressure by 10–15 mmHg【1】.
Screen for secondary causes when hypertension remains severe: primary aldosteronism (aldosterone‑renin ratio), obstructive sleep apnea, and renal artery stenosis【2】.
Review concomitant substances that raise BP (NSAIDs, decongestants, oral contraceptives, corticosteroids)【2】 and excessive alcohol intake (>2 drinks/day men, >1 drink/day women)【5】.

Reassess blood pressure 2–4 weeks after initiating the thiazide‑like diuretic【1】【3】【4】.
Achieve target blood pressure within 3 months of starting the triple regimen【1】【3】【4】.

Adding a thiazide‑like diuretic to ARB + CCB therapy yields an additional systolic reduction of 8–12 mmHg and diastolic reduction of 4–6 mmHg, sufficient to bring most patients to guideline targets【1】.

If blood pressure remains ≥ 140/90 mmHg after 3 months on optimal triple therapy, the condition is classified as resistant hypertension【2】.
Spironolactone 25 mg once daily is the preferred fourth‑line agent when serum potassium is < 4.5 mmol/L and eGFR > 45 mL/min/1.73 m²【1】【2】【3】.
Alternatives when spironolactone is contraindicated:
- Amiloride 5–10 mg daily【1】【2】【3】
- Doxazosin 4–8 mg daily【1】【2】【3】
- Beta‑blocker (if a compelling indication such as coronary disease or heart failure exists)【1】【5】.
Resistant hypertension should be referred to specialist hypertension centers for advanced evaluation【2】【3】.

Do not combine telmisartan with an ACE inhibitor because of increased risk of hyperkalemia, hypotension, and acute kidney injury【4】.
Avoid immediate‑release nifedipine capsules; only extended‑release formulations are recommended due to cardiovascular safety concerns【7】.
Monitor for orthostatic hypotension, especially in older adults, by checking standing blood pressure【2】【5】.